Literature DB >> 28982263

A simulation study of outcome adaptive randomization in multi-arm clinical trials.

J Kyle Wathen1, Peter F Thall2.   

Abstract

Randomizing patients among treatments with equal probabilities in clinical trials is the established method to obtain unbiased comparisons. In recent years, motivated by ethical considerations, many authors have proposed outcome adaptive randomization, wherein the randomization probabilities are unbalanced, based on interim data, to favor treatment arms having more favorable outcomes. While there has been substantial controversy regarding the merits and flaws of adaptive versus equal randomization, there has not yet been a systematic simulation study in the multi-arm setting. A simulation study was conducted to evaluate four different Bayesian adaptive randomization methods and compare them to equal randomization in five-arm clinical trials. All adaptive randomization methods included an initial burn-in with equal randomization and some combination of other modifications to avoid extreme randomization probabilities. Trials either with or without a control arm were evaluated, using designs that may terminate arms early for futility and select one or more experimental treatments at the end. The designs were evaluated under a range of scenarios and sample sizes. For trials with a control arm and maximum same size 250 or 500, several commonly used adaptive randomization methods have very low probabilities of correctly selecting a truly superior treatment. Of those studied, the only adaptive randomization method with desirable properties has a burn-in with equal randomization and thereafter randomization probabilities restricted to the interval 0.10-0.90. Compared to equal randomization, this method has a favorable sample size imbalance but lower probability of correctly selecting a superior treatment. In multi-arm trials, compared to equal randomization, several commonly used adaptive randomization methods give much lower probabilities of selecting superior treatments. Aside from randomization method, conducting a multi-arm trial without a control arm may lead to very low probabilities of selecting any superior treatments if differences between the treatment success probabilities are small.

Entities:  

Keywords:  Adaptive randomization; Bayesian design; play the winner; screening trial; simulation

Mesh:

Year:  2017        PMID: 28982263      PMCID: PMC5634533          DOI: 10.1177/1740774517692302

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  19 in total

Review 1.  Adaptive randomization for clinical trials.

Authors:  William F Rosenberger; Oleksandr Sverdlov; Feifang Hu
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

2.  Adaptive clinical trials: the promise and the caution.

Authors:  Donald A Berry
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

3.  Commentary on Hey and Kimmelman.

Authors:  Marc Buyse
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

4.  The platform trial: an efficient strategy for evaluating multiple treatments.

Authors:  Scott M Berry; Jason T Connor; Roger J Lewis
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

Review 5.  Practical Bayesian adaptive randomisation in clinical trials.

Authors:  Peter F Thall; J Kyle Wathen
Journal:  Eur J Cancer       Date:  2007-02-16       Impact factor: 9.162

6.  Worth adapting? Revisiting the usefulness of outcome-adaptive randomization.

Authors:  J Jack Lee; Nan Chen; Guosheng Yin
Journal:  Clin Cancer Res       Date:  2012-07-02       Impact factor: 12.531

7.  Commentary on Hey and Kimmelman.

Authors:  J Jack Lee
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

8.  Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.

Authors:  Francis J Giles; Hagop M Kantarjian; Jorge E Cortes; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Deborah A Thomas; Alessandra Ferrajoli; Susan O'Brien; Jay K Wathen; Lian-Chun Xiao; Donald A Berry; Elihu H Estey
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

Review 9.  A group sequential, response-adaptive design for randomized clinical trials.

Authors:  Theodore G Karrison; Dezheng Huo; Rick Chappell
Journal:  Control Clin Trials       Date:  2003-10

Review 10.  The use of response-adaptive designs in clinical trials.

Authors:  W F Rosenberger; J M Lachin
Journal:  Control Clin Trials       Date:  1993-12
View more
  16 in total

1.  A nonparametric Bayesian basket trial design.

Authors:  Yanxun Xu; Peter Müller; Apostolia M Tsimberidou; Donald Berry
Journal:  Biom J       Date:  2018-05-28       Impact factor: 2.207

2.  Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.

Authors:  Rebecca S Slack Tidwell; S Andrew Peng; Minxing Chen; Diane D Liu; Ying Yuan; J Jack Lee
Journal:  Clin Trials       Date:  2019-08-26       Impact factor: 2.486

3.  Adaptive Enrichment Designs in Clinical Trials.

Authors:  Peter F Thall
Journal:  Annu Rev Stat Appl       Date:  2021-03       Impact factor: 7.917

4.  Using Adaptive Designs to Avoid Selecting the Wrong Arms in Multiarm Comparative Effectiveness Trials.

Authors:  Byron J Gajewski; Jeffrey Statland; Richard Barohn
Journal:  Stat Biopharm Res       Date:  2019-06-26       Impact factor: 1.452

5.  A Signature Enrichment Design with Bayesian Adaptive Randomization.

Authors:  Fang Xia; Stephen L George; Jing Ning; Liang Li; Xuelin Huang
Journal:  J Appl Stat       Date:  2020-04-27       Impact factor: 1.404

Review 6.  Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges.

Authors:  Moreno Ursino; Nigel Stallard
Journal:  Int J Environ Res Public Health       Date:  2021-01-24       Impact factor: 3.390

7.  The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.

Authors:  Alessio Crippa; Bram De Laere; Andrea Discacciati; Berit Larsson; Jason T Connor; Erin E Gabriel; Camilla Thellenberg; Elin Jänes; Gunilla Enblad; Anders Ullen; Marie Hjälm-Eriksson; Jan Oldenburg; Piet Ost; Johan Lindberg; Martin Eklund; Henrik Grönberg
Journal:  Trials       Date:  2020-06-26       Impact factor: 2.279

8.  Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.

Authors:  Elizabeth G Ryan; Sarah E Lamb; Esther Williamson; Simon Gates
Journal:  Trials       Date:  2020-01-14       Impact factor: 2.728

Review 9.  The Bayesian Design of Adaptive Clinical Trials.

Authors:  Alessandra Giovagnoli
Journal:  Int J Environ Res Public Health       Date:  2021-01-10       Impact factor: 3.390

Review 10.  Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials.

Authors:  Chengxing Cindy Lu; Xiaoyun Nicole Li; Kristine Broglio; Paul Bycott; Qi Jiang; Xiaoming Li; Anna McGlothlin; Hong Tian; Jingjing Ye
Journal:  Ther Innov Regul Sci       Date:  2021-06-23       Impact factor: 1.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.